Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax Plus Zanubrutinib vs Venetoclax Plus Acalabrutinib in Untreated CLL
NCT07277231Phase 3Recruiting
- Sponsor
- BeOne Medicines
- Start
- Jan 2026
- Primary completion
- Feb 2031
- Countries
- 17
01
Overview
A Phase 3 trial of sonrotoclax in chronic lymphocytic leukemia (CLL), sponsored by BeOne Medicines. Started Jan 2026; status: recruiting.
02
Drugs
sonrotoclax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT07277231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07277231.